Amring Pharmaceuticals Inc. (Amring), a generic pharmaceutical company, announced entering into an agreement with Ferring International Center S.A. on December 1, 2020 that will further strengthen its position in the marketplace with the acquisition of the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB). Amring has been marketing the authorized generic version of LYSTEDA in the USA since March 14, 2016.
“With the acquisition of LYSTEDA, Amring is further securing its position as a market leader in the treatment of HMB and expands product opportunities in markets outside of the USA,” stated Daniel Carbery, President and CEO of Amring. “We believe that this brings long term value to patients and customers in our target markets.”
Source: Biospace